ENDPOINTS NEWS2h
Ex­clu­sive: Buck­ing gene-edit­ing down­turn, Tune rais­es $175M to bring epi­ge­net­ic edit­ing to clin­ic
Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...